Chemoprevention of rat hepatocarcinogenesis with histone deacetylase inhibitors: Efficacy of tributyrin, a butyric acid prodrug


Autoria(s): KUROIWA-TRZMIELINA, Joice; CONTI, Aline de; SCOLASTICI, Clarissa; PEREIRA, Douglas; HORST, Maria Aderuza; PURGATTO, Eduardo; Ong, Thomas Prates; Moreno, Fernando Salvador
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

19/10/2012

19/10/2012

2009

Resumo

Hepatocellular carcinoma (HCC) ranks in prevalence and mortality among top 10 cancers worldwide. Butyric acid (BA), a member of histone deacetylase inhibitors (HDACi) has been proposed as an anticareinogenic agent. However, its short half-life is a therapeutical limitation. This problem could be circumvented with tributyrin (TB), a proposed BA prodrug. To investigate TB effectiveness for chemoprevention, rats were treated with the compound during initial phases of ""resistant hepatocyte"" model of hepatocarcinogenesis, and cellular and molecular parameters were evaluated. TB inhibited (p < 0.05) development of hepatic preneoplastic lesions (PNL) including persistent ones considered HCC progression sites. TB increased (p < 0.05) PNL remodeling, a process whereby they tend to disappear. TB did not inhibit cell proliferation in PNL, but induced (p < 0.05) apoptosis in remodeling ones. Compared to controls, rats treated with TB presented increased (P < 0.05) hepatic levels of BA indicating its effectiveness as a prodrug. Molecular mechanisms of TB-induced hepatocarcinogenesis chemoprevention were investigated. TB increased (p < 0.05) hepatic nuclear histone H3K9 hyperacetylation specifically in PNL and p21 protein expression, which could be associated with inhibitory HDAC effects. Moreover, it reduced (p < 0.05) the frequency of persistent PNL with aberrant cytoplasmic p53 accumulation, an alteration associated with increased malignancy. Original data observed in our study support the effectiveness of TB as a prodrug of BA and as an HDACi in hepatocarcinogenesis chemoprevention. Besides histone acetylation and p21 restored expression, molecular mechanisms involved with TB anticarcinogenic actions could also be related to modulation of p53 pathways. (C) 2008 Wiley-Liss, Inc.

FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo)

CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior)

CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico)

Identificador

INTERNATIONAL JOURNAL OF CANCER, v.124, n.11, p.2520-2527, 2009

0020-7136

http://producao.usp.br/handle/BDPI/19867

10.1002/ijc.24212

http://dx.doi.org/10.1002/ijc.24212

Idioma(s)

eng

Publicador

WILEY-LISS

Relação

International Journal of Cancer

Direitos

restrictedAccess

Copyright WILEY-LISS

Palavras-Chave #hepatocarcinogenesis #chemoprevention #historic deacetylase inhibitors #tributyrin #butyric acid #POSITIVE PRENEOPLASTIC LESIONS #ABERRANT CRYPT FOCI #HEPATOCELLULAR-CARCINOMA #SODIUM-BUTYRATE #CANCER CHEMOPREVENTION #LIVER CARCINOGENESIS #CELL-PROLIFERATION #DISTINCT ACTIONS #INITIAL PHASES #COLON-CANCER #Oncology
Tipo

article

original article

publishedVersion